<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/">

	<channel><title><![CDATA[Latest Publisher Reports]]></title><atom:link href="http://www.researchmoz.com/publisher" rel="self" type="application/rss+xml" />
	<link>http://www.researchmoz.com</link>
	<description><![CDATA[Latest Publisher Reports]]></description>
	<lastBuildDate>Wed, 18 Jul 2012 12:20:54 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator><item><title>Biotron Limited - Product Pipeline Review - 2013</title><link>http://www.researchmoz.com/biotron-limited-product-pipeline-review-2013-report.html</link><comments>http://www.researchmoz.com/biotron-limited-product-pipeline-review-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/biotron-limited-product-pipeline-review-2013-report.html</guid><description><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;Biotron Limited - Product Pipeline Review - 2013&rdquo; provides data on the Biotron Limited&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, Biotron Limited&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from Biotron Limited and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



Biotron Limited - Brief Biotron Limited overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of Biotron Limited human therapeutic division.
Overview of pipeline therapeutics across various the <br><br>Original Post <a href=http://www.researchmoz.com/biotron-limited-product-pipeline-review-2013-report.html>Biotron Limited - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;Biotron Limited - Product Pipeline Review - 2013&rdquo; provides data on the Biotron Limited&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, Biotron Limited&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from Biotron Limited and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



Biotron Limited - Brief Biotron Limited overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of Biotron Limited human therapeutic division.
Overview of pipeline therapeutics across various the <br><br>Original Post <a href=http://www.researchmoz.com/biotron-limited-product-pipeline-review-2013-report.html>Biotron Limited - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/biotron-limited-product-pipeline-review-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>CEL-SCI Corporation - Product Pipeline Review - 2013</title><link>http://www.researchmoz.com/cel-sci-corporation-product-pipeline-review-2013-report.html</link><comments>http://www.researchmoz.com/cel-sci-corporation-product-pipeline-review-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cel-sci-corporation-product-pipeline-review-2013-report.html</guid><description><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;CEL-SCI Corporation - Product Pipeline Review - 2013&rdquo; provides data on the CEL-SCI Corporation&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, CEL-SCI Corporation&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from CEL-SCI Corporation and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



CEL-SCI Corporation - Brief CEL-SCI Corporation overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of CEL-SCI Corporation human therapeutic division.
Overview of pipeline the <br><br>Original Post <a href=http://www.researchmoz.com/cel-sci-corporation-product-pipeline-review-2013-report.html>CEL-SCI Corporation - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;CEL-SCI Corporation - Product Pipeline Review - 2013&rdquo; provides data on the CEL-SCI Corporation&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, CEL-SCI Corporation&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from CEL-SCI Corporation and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



CEL-SCI Corporation - Brief CEL-SCI Corporation overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of CEL-SCI Corporation human therapeutic division.
Overview of pipeline the <br><br>Original Post <a href=http://www.researchmoz.com/cel-sci-corporation-product-pipeline-review-2013-report.html>CEL-SCI Corporation - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cel-sci-corporation-product-pipeline-review-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Chelsea Therapeutics International Ltd. - Product Pipeline Review - 2013</title><link>http://www.researchmoz.com/chelsea-therapeutics-international-ltd-product-pipeline-review-2013-report.html</link><comments>http://www.researchmoz.com/chelsea-therapeutics-international-ltd-product-pipeline-review-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/chelsea-therapeutics-international-ltd-product-pipeline-review-2013-report.html</guid><description><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;Chelsea Therapeutics International Ltd. - Product Pipeline Review - 2013&rdquo; provides data on the Chelsea Therapeutics International Ltd.&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, Chelsea Therapeutics International Ltd.&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from Chelsea Therapeutics International Ltd. and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



Chelsea Therapeutics International Ltd. - Brief Chelsea Therapeutics International Ltd. overview including business description, key information and facts, and its locations an <br><br>Original Post <a href=http://www.researchmoz.com/chelsea-therapeutics-international-ltd-product-pipeline-review-2013-report.html>Chelsea Therapeutics International Ltd. - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;Chelsea Therapeutics International Ltd. - Product Pipeline Review - 2013&rdquo; provides data on the Chelsea Therapeutics International Ltd.&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, Chelsea Therapeutics International Ltd.&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from Chelsea Therapeutics International Ltd. and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



Chelsea Therapeutics International Ltd. - Brief Chelsea Therapeutics International Ltd. overview including business description, key information and facts, and its locations an <br><br>Original Post <a href=http://www.researchmoz.com/chelsea-therapeutics-international-ltd-product-pipeline-review-2013-report.html>Chelsea Therapeutics International Ltd. - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/chelsea-therapeutics-international-ltd-product-pipeline-review-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Advaxis, Inc. - Product Pipeline Review - 2013</title><link>http://www.researchmoz.com/advaxis-inc-product-pipeline-review-2013-report.html</link><comments>http://www.researchmoz.com/advaxis-inc-product-pipeline-review-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/advaxis-inc-product-pipeline-review-2013-report.html</guid><description><![CDATA[Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;Advaxis, Inc. - Product Pipeline Review - 2013&rdquo; provides data on the Advaxis, Inc.&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, Advaxis, Inc.&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from Advaxis, Inc. and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope


Advaxis, Inc. - Brief Advaxis, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of Advaxis, Inc. human therapeutic division.
Overview of pipeline therapeutics across various therapy areas.
Cover <br><br>Original Post <a href=http://www.researchmoz.com/advaxis-inc-product-pipeline-review-2013-report.html>Advaxis, Inc. - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;Advaxis, Inc. - Product Pipeline Review - 2013&rdquo; provides data on the Advaxis, Inc.&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, Advaxis, Inc.&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from Advaxis, Inc. and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope


Advaxis, Inc. - Brief Advaxis, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of Advaxis, Inc. human therapeutic division.
Overview of pipeline therapeutics across various therapy areas.
Cover <br><br>Original Post <a href=http://www.researchmoz.com/advaxis-inc-product-pipeline-review-2013-report.html>Advaxis, Inc. - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/advaxis-inc-product-pipeline-review-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>NPS Pharmaceuticals, Inc. - Product Pipeline Review - 2013</title><link>http://www.researchmoz.com/nps-pharmaceuticals-inc-product-pipeline-review-2013-report.html</link><comments>http://www.researchmoz.com/nps-pharmaceuticals-inc-product-pipeline-review-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/nps-pharmaceuticals-inc-product-pipeline-review-2013-report.html</guid><description><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;NPS Pharmaceuticals, Inc. - Product Pipeline Review - 2013&rdquo; provides data on the NPS Pharmaceuticals, Inc.&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, NPS Pharmaceuticals, Inc.&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from NPS Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



NPS Pharmaceuticals, Inc. - Brief NPS Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of NPS Pharmaceuticals, Inc. human thera <br><br>Original Post <a href=http://www.researchmoz.com/nps-pharmaceuticals-inc-product-pipeline-review-2013-report.html>NPS Pharmaceuticals, Inc. - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;NPS Pharmaceuticals, Inc. - Product Pipeline Review - 2013&rdquo; provides data on the NPS Pharmaceuticals, Inc.&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, NPS Pharmaceuticals, Inc.&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from NPS Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



NPS Pharmaceuticals, Inc. - Brief NPS Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of NPS Pharmaceuticals, Inc. human thera <br><br>Original Post <a href=http://www.researchmoz.com/nps-pharmaceuticals-inc-product-pipeline-review-2013-report.html>NPS Pharmaceuticals, Inc. - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/nps-pharmaceuticals-inc-product-pipeline-review-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Leg Ulcers - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/leg-ulcers-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/leg-ulcers-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/leg-ulcers-pipeline-review-h1-2013-report.html</guid><description><![CDATA[
Summary

Global Markets Direct&rsquo;s, 'Leg Ulcers - Pipeline Review, H2 2013', provides an overview of the indication&rsquo;s therapeutic pipeline. This report provides information on the therapeutic development for Leg Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leg Ulcers. Leg Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Leg Ulcers.
A review  <br><br>Original Post <a href=http://www.researchmoz.com/leg-ulcers-pipeline-review-h1-2013-report.html>Leg Ulcers - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
Summary

Global Markets Direct&rsquo;s, 'Leg Ulcers - Pipeline Review, H2 2013', provides an overview of the indication&rsquo;s therapeutic pipeline. This report provides information on the therapeutic development for Leg Ulcers, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leg Ulcers. Leg Ulcers - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Leg Ulcers.
A review  <br><br>Original Post <a href=http://www.researchmoz.com/leg-ulcers-pipeline-review-h1-2013-report.html>Leg Ulcers - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/leg-ulcers-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bioniche Life Sciences, Inc. - Product Pipeline Review - 2013</title><link>http://www.researchmoz.com/bioniche-life-sciences-inc-product-pipeline-review-2013-report.html</link><comments>http://www.researchmoz.com/bioniche-life-sciences-inc-product-pipeline-review-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bioniche-life-sciences-inc-product-pipeline-review-2013-report.html</guid><description><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;Bioniche Life Sciences, Inc. - Product Pipeline Review - 2013&rdquo; provides data on the Bioniche Life Sciences, Inc.&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, Bioniche Life Sciences, Inc.&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from Bioniche Life Sciences, Inc. and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



Bioniche Life Sciences, Inc. - Brief Bioniche Life Sciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of Bioniche Life Scien <br><br>Original Post <a href=http://www.researchmoz.com/bioniche-life-sciences-inc-product-pipeline-review-2013-report.html>Bioniche Life Sciences, Inc. - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;Bioniche Life Sciences, Inc. - Product Pipeline Review - 2013&rdquo; provides data on the Bioniche Life Sciences, Inc.&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, Bioniche Life Sciences, Inc.&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from Bioniche Life Sciences, Inc. and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



Bioniche Life Sciences, Inc. - Brief Bioniche Life Sciences, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of Bioniche Life Scien <br><br>Original Post <a href=http://www.researchmoz.com/bioniche-life-sciences-inc-product-pipeline-review-2013-report.html>Bioniche Life Sciences, Inc. - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bioniche-life-sciences-inc-product-pipeline-review-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>CytRx Corporation - Product Pipeline Review - 2013</title><link>http://www.researchmoz.com/cytrx-corporation-product-pipeline-review-2013-report.html</link><comments>http://www.researchmoz.com/cytrx-corporation-product-pipeline-review-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cytrx-corporation-product-pipeline-review-2013-report.html</guid><description><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;CytRx Corporation - Product Pipeline Review - 2013&rdquo; provides data on the CytRx Corporation&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, CytRx Corporation&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from CytRx Corporation and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



CytRx Corporation - Brief CytRx Corporation overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of CytRx Corporation human therapeutic division.
Overview of pipeline therapeutics acro <br><br>Original Post <a href=http://www.researchmoz.com/cytrx-corporation-product-pipeline-review-2013-report.html>CytRx Corporation - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;CytRx Corporation - Product Pipeline Review - 2013&rdquo; provides data on the CytRx Corporation&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, CytRx Corporation&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from CytRx Corporation and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



CytRx Corporation - Brief CytRx Corporation overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of CytRx Corporation human therapeutic division.
Overview of pipeline therapeutics acro <br><br>Original Post <a href=http://www.researchmoz.com/cytrx-corporation-product-pipeline-review-2013-report.html>CytRx Corporation - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cytrx-corporation-product-pipeline-review-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>The Medicines Company - Product Pipeline Review - 2013</title><link>http://www.researchmoz.com/the-medicines-company-product-pipeline-review-2013-report.html</link><comments>http://www.researchmoz.com/the-medicines-company-product-pipeline-review-2013-report.html#comments</comments><pubDate>Tue, 30 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/the-medicines-company-product-pipeline-review-2013-report.html</guid><description><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;The Medicines Company - Product Pipeline Review - 2013&rdquo; provides data on the The Medicines Company&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, The Medicines Company&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from The Medicines Company and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



The Medicines Company - Brief The Medicines Company overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of The Medicines Company human therapeutic division.
Overview o <br><br>Original Post <a href=http://www.researchmoz.com/the-medicines-company-product-pipeline-review-2013-report.html>The Medicines Company - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
Summary

Global Market Direct&rsquo;s pharmaceuticals report, &ldquo;The Medicines Company - Product Pipeline Review - 2013&rdquo; provides data on the The Medicines Company&rsquo;s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.&nbsp;

This report is built using data and information sourced from Global Markets Direct&rsquo;s proprietary databases, The Medicines Company&rsquo;s corporate website, SEC filings, investor presentations and featured press releases, both from The Medicines Company and industry-specific third party sources, put together by Global Markets Direct&rsquo;s team.&nbsp;

Scope



The Medicines Company - Brief The Medicines Company overview including business description, key information and facts, and its locations and subsidiaries.
Review of current pipeline of The Medicines Company human therapeutic division.
Overview o <br><br>Original Post <a href=http://www.researchmoz.com/the-medicines-company-product-pipeline-review-2013-report.html>The Medicines Company - Product Pipeline Review - 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/the-medicines-company-product-pipeline-review-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Gram-Positive Bacterial Infections -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Gram-Positive Bacterial Infections -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Gram-Positive Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Gram-Positive Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of  <br><br>Original Post <a href=http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html>Gram-Positive Bacterial Infections -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Gram-Positive Bacterial Infections -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Gram-Positive Bacterial Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Gram-Positive Bacterial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gram-Positive Bacterial Infections. Gram-Positive Bacterial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of  <br><br>Original Post <a href=http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html>Gram-Positive Bacterial Infections -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/gram-positive-bacterial-infections-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cutaneous T-Cell Lymphoma -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Cutaneous T-Cell Lymphoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snaps <br><br>Original Post <a href=http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html>Cutaneous T-Cell Lymphoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Cutaneous T-Cell Lymphoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Cutaneous T-Cell Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous T-Cell Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous T-Cell Lymphoma. Cutaneous T-Cell Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snaps <br><br>Original Post <a href=http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html>Cutaneous T-Cell Lymphoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cutaneous-t-cell-lymphoma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Burns -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Burns -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Burns - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burns. Burns - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Burns.- A review of the Burns products under development  <br><br>Original Post <a href=http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html>Burns -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Burns -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Burns - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Burns, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burns. Burns - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Burns.- A review of the Burns products under development  <br><br>Original Post <a href=http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html>Burns -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/burns-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Indolent Lymphoma -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Indolent Lymphoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Indolent Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. Indolent Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html>Indolent Lymphoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Indolent Lymphoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Indolent Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Indolent Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Indolent Lymphoma. Indolent Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html>Indolent Lymphoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/indolent-lymphoma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Myelofibrosis -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Myelofibrosis -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Myelofibrosis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Myelofibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelofibrosis. Myelofibrosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Myelofibrosis.- A <br><br>Original Post <a href=http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html>Myelofibrosis -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Myelofibrosis -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Myelofibrosis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Myelofibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Myelofibrosis. Myelofibrosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Myelofibrosis.- A <br><br>Original Post <a href=http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html>Myelofibrosis -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/myelofibrosis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Osteosarcoma -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Osteosarcoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Osteosarcoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Osteosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteosarcoma. Osteosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Osteosarcoma.- A revie <br><br>Original Post <a href=http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html>Osteosarcoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Osteosarcoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Osteosarcoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Osteosarcoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteosarcoma. Osteosarcoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Osteosarcoma.- A revie <br><br>Original Post <a href=http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html>Osteosarcoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/osteosarcoma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Psychiatric Disorders -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Psychiatric Disorders -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Psychiatric Disorders - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychiatric Disorders. Psychiatric Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global th <br><br>Original Post <a href=http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html>Psychiatric Disorders -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Psychiatric Disorders -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Psychiatric Disorders - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Psychiatric Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psychiatric Disorders. Psychiatric Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global th <br><br>Original Post <a href=http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html>Psychiatric Disorders -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/psychiatric-disorders-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Waldenstrom Macroglobulinemia -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Waldenstrom Macroglobulinemia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Waldenstrom Macroglobulinemia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia. Waldenstrom Macroglobulinemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated di <br><br>Original Post <a href=http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html>Waldenstrom Macroglobulinemia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Waldenstrom Macroglobulinemia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Waldenstrom Macroglobulinemia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Waldenstrom Macroglobulinemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Waldenstrom Macroglobulinemia. Waldenstrom Macroglobulinemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated di <br><br>Original Post <a href=http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html>Waldenstrom Macroglobulinemia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/waldenstrom-macroglobulinemia-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Post Menopausal Osteoporosis -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Post Menopausal Osteoporosis -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Post Menopausal Osteoporosis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis. Post Menopausal Osteoporosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease <br><br>Original Post <a href=http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html>Post Menopausal Osteoporosis -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Post Menopausal Osteoporosis -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Post Menopausal Osteoporosis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Post Menopausal Osteoporosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post Menopausal Osteoporosis. Post Menopausal Osteoporosis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease <br><br>Original Post <a href=http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html>Post Menopausal Osteoporosis -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/post-menopausal-osteoporosis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Post-Traumatic Stress Disorder (PTSD) -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Post-Traumatic Stress Disorder (PTSD) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD). Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability an <br><br>Original Post <a href=http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html>Post-Traumatic Stress Disorder (PTSD) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Post-Traumatic Stress Disorder (PTSD) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Post-Traumatic Stress Disorder (PTSD), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-Traumatic Stress Disorder (PTSD). Post-Traumatic Stress Disorder (PTSD) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability an <br><br>Original Post <a href=http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html>Post-Traumatic Stress Disorder (PTSD) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/post-traumatic-stress-disorder-ptsd-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Septic Shock -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/septic-shock-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/septic-shock-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/septic-shock-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Septic Shock -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Septic Shock - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Septic Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Septic Shock. Septic Shock - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Septic Shock.- A revie <br><br>Original Post <a href=http://www.researchmoz.com/septic-shock-pipeline-review-h1-2013-report.html>Septic Shock -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Septic Shock -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Septic Shock - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Septic Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Septic Shock. Septic Shock - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Septic Shock.- A revie <br><br>Original Post <a href=http://www.researchmoz.com/septic-shock-pipeline-review-h1-2013-report.html>Septic Shock -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/septic-shock-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Streptococcal Infections -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/streptococcal-infections-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/streptococcal-infections-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/streptococcal-infections-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Streptococcal Infections -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Streptococcal Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Streptococcal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Streptococcal Infections. Streptococcal Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot o <br><br>Original Post <a href=http://www.researchmoz.com/streptococcal-infections-pipeline-review-h1-2013-report.html>Streptococcal Infections -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Streptococcal Infections -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Streptococcal Infections - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Streptococcal Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Streptococcal Infections. Streptococcal Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot o <br><br>Original Post <a href=http://www.researchmoz.com/streptococcal-infections-pipeline-review-h1-2013-report.html>Streptococcal Infections -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/streptococcal-infections-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Ischemic Stroke -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/ischemic-stroke-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/ischemic-stroke-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/ischemic-stroke-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Ischemic Stroke -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Ischemic Stroke - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Ischemi <br><br>Original Post <a href=http://www.researchmoz.com/ischemic-stroke-pipeline-review-h1-2013-report.html>Ischemic Stroke -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Ischemic Stroke -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Ischemic Stroke - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ischemic Stroke, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemic Stroke. Ischemic Stroke - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Ischemi <br><br>Original Post <a href=http://www.researchmoz.com/ischemic-stroke-pipeline-review-h1-2013-report.html>Ischemic Stroke -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/ischemic-stroke-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Choroidal Neovascularization -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/choroidal-neovascularization-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/choroidal-neovascularization-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/choroidal-neovascularization-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Choroidal Neovascularization -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Choroidal Neovascularization - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Choroidal Neovascularization, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Choroidal Neovascularization. Choroidal Neovascularization - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease <br><br>Original Post <a href=http://www.researchmoz.com/choroidal-neovascularization-pipeline-review-h1-2013-report.html>Choroidal Neovascularization -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Choroidal Neovascularization -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Choroidal Neovascularization - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Choroidal Neovascularization, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Choroidal Neovascularization. Choroidal Neovascularization - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease <br><br>Original Post <a href=http://www.researchmoz.com/choroidal-neovascularization-pipeline-review-h1-2013-report.html>Choroidal Neovascularization -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/choroidal-neovascularization-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specif <br><br>Original Post <a href=http://www.researchmoz.com/idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-pipeline-review-h1-2013-report.html>Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura). Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specif <br><br>Original Post <a href=http://www.researchmoz.com/idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-pipeline-review-h1-2013-report.html>Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/idiopathic-thrombocytopenic-purpura-immune-thrombocytopenic-purpura-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Diphtheria -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/diphtheria-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/diphtheria-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/diphtheria-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Diphtheria -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Diphtheria - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diphtheria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diphtheria. Diphtheria - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Diphtheria.- A review of the Dip <br><br>Original Post <a href=http://www.researchmoz.com/diphtheria-pipeline-review-h1-2013-report.html>Diphtheria -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Diphtheria -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Diphtheria - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diphtheria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diphtheria. Diphtheria - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Diphtheria.- A review of the Dip <br><br>Original Post <a href=http://www.researchmoz.com/diphtheria-pipeline-review-h1-2013-report.html>Diphtheria -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/diphtheria-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Metastatic Lung Cancer -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/metastatic-lung-cancer-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/metastatic-lung-cancer-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/metastatic-lung-cancer-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Metastatic Lung Cancer -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Metastatic Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Lung Cancer. Metastatic Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the glob <br><br>Original Post <a href=http://www.researchmoz.com/metastatic-lung-cancer-pipeline-review-h1-2013-report.html>Metastatic Lung Cancer -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Metastatic Lung Cancer -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Metastatic Lung Cancer - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Lung Cancer. Metastatic Lung Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the glob <br><br>Original Post <a href=http://www.researchmoz.com/metastatic-lung-cancer-pipeline-review-h1-2013-report.html>Metastatic Lung Cancer -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/metastatic-lung-cancer-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Uterine Cancer -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/uterine-cancer-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/uterine-cancer-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/uterine-cancer-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Uterine Cancer -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Uterine Cancer - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Uterine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Cancer. Uterine Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Uterine Canc <br><br>Original Post <a href=http://www.researchmoz.com/uterine-cancer-pipeline-review-h1-2013-report.html>Uterine Cancer -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Uterine Cancer -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Uterine Cancer - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Uterine Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Uterine Cancer. Uterine Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Uterine Canc <br><br>Original Post <a href=http://www.researchmoz.com/uterine-cancer-pipeline-review-h1-2013-report.html>Uterine Cancer -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/uterine-cancer-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Rabies -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/rabies-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/rabies-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/rabies-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Rabies -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Rabies - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Rabies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rabies. Rabies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Rabies.- A review of the Rabies products under devel <br><br>Original Post <a href=http://www.researchmoz.com/rabies-pipeline-review-h1-2013-report.html>Rabies -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Rabies -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Rabies - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Rabies, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rabies. Rabies - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Rabies.- A review of the Rabies products under devel <br><br>Original Post <a href=http://www.researchmoz.com/rabies-pipeline-review-h1-2013-report.html>Rabies -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/rabies-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Chronic Plaque Psoriasis -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/chronic-plaque-psoriasis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/chronic-plaque-psoriasis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/chronic-plaque-psoriasis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Chronic Plaque Psoriasis -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Chronic Plaque Psoriasis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chronic Plaque Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis. Chronic Plaque Psoriasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot o <br><br>Original Post <a href=http://www.researchmoz.com/chronic-plaque-psoriasis-pipeline-review-h1-2013-report.html>Chronic Plaque Psoriasis -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Chronic Plaque Psoriasis -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Chronic Plaque Psoriasis - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chronic Plaque Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis. Chronic Plaque Psoriasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot o <br><br>Original Post <a href=http://www.researchmoz.com/chronic-plaque-psoriasis-pipeline-review-h1-2013-report.html>Chronic Plaque Psoriasis -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/chronic-plaque-psoriasis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Neuroendocrine Tumors -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/neuroendocrine-tumors-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/neuroendocrine-tumors-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/neuroendocrine-tumors-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Neuroendocrine Tumors -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Neuroendocrine Tumors - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroendocrine Tumors. Neuroendocrine Tumors - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global th <br><br>Original Post <a href=http://www.researchmoz.com/neuroendocrine-tumors-pipeline-review-h1-2013-report.html>Neuroendocrine Tumors -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Neuroendocrine Tumors -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Neuroendocrine Tumors - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Neuroendocrine Tumors, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuroendocrine Tumors. Neuroendocrine Tumors - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global th <br><br>Original Post <a href=http://www.researchmoz.com/neuroendocrine-tumors-pipeline-review-h1-2013-report.html>Neuroendocrine Tumors -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/neuroendocrine-tumors-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Partial Seizure -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/partial-seizure-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/partial-seizure-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/partial-seizure-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Partial Seizure -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Partial Seizure - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Partial Seizure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Partial Seizure. Partial Seizure - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Partial <br><br>Original Post <a href=http://www.researchmoz.com/partial-seizure-pipeline-review-h1-2013-report.html>Partial Seizure -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Partial Seizure -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Partial Seizure - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Partial Seizure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Partial Seizure. Partial Seizure - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Partial <br><br>Original Post <a href=http://www.researchmoz.com/partial-seizure-pipeline-review-h1-2013-report.html>Partial Seizure -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/partial-seizure-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Sarcopenia -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/sarcopenia-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/sarcopenia-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/sarcopenia-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Sarcopenia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Sarcopenia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sarcopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcopenia. Sarcopenia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Sarcopenia.- A review of the Sar <br><br>Original Post <a href=http://www.researchmoz.com/sarcopenia-pipeline-review-h1-2013-report.html>Sarcopenia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Sarcopenia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Sarcopenia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sarcopenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcopenia. Sarcopenia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Sarcopenia.- A review of the Sar <br><br>Original Post <a href=http://www.researchmoz.com/sarcopenia-pipeline-review-h1-2013-report.html>Sarcopenia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/sarcopenia-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Interstitial Cystitis (Painful Bladder Syndrome) -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/interstitial-cystitis-painful-bladder-syndrome-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/interstitial-cystitis-painful-bladder-syndrome-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/interstitial-cystitis-painful-bladder-syndrome-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Interstitial Cystitis (Painful Bladder Syndrome) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome). Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report <br><br>Original Post <a href=http://www.researchmoz.com/interstitial-cystitis-painful-bladder-syndrome-pipeline-review-h1-2013-report.html>Interstitial Cystitis (Painful Bladder Syndrome) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Interstitial Cystitis (Painful Bladder Syndrome) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome). Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report <br><br>Original Post <a href=http://www.researchmoz.com/interstitial-cystitis-painful-bladder-syndrome-pipeline-review-h1-2013-report.html>Interstitial Cystitis (Painful Bladder Syndrome) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/interstitial-cystitis-painful-bladder-syndrome-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Pruritus -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/pruritus-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/pruritus-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pruritus-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Pruritus -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Pruritus - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pruritus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pruritus. Pruritus - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Pruritus.- A review of the Pruritus produc <br><br>Original Post <a href=http://www.researchmoz.com/pruritus-pipeline-review-h1-2013-report.html>Pruritus -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Pruritus -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Pruritus - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pruritus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pruritus. Pruritus - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Pruritus.- A review of the Pruritus produc <br><br>Original Post <a href=http://www.researchmoz.com/pruritus-pipeline-review-h1-2013-report.html>Pruritus -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pruritus-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>B-Cell Chronic Lymphocytic Leukemia -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/b-cell-chronic-lymphocytic-leukemia-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/b-cell-chronic-lymphocytic-leukemia-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/b-cell-chronic-lymphocytic-leukemia-pipeline-review-h1-2013-report.html</guid><description><![CDATA[B-Cell Chronic Lymphocytic Leukemia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia. B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevanc <br><br>Original Post <a href=http://www.researchmoz.com/b-cell-chronic-lymphocytic-leukemia-pipeline-review-h1-2013-report.html>B-Cell Chronic Lymphocytic Leukemia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[B-Cell Chronic Lymphocytic Leukemia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia. B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevanc <br><br>Original Post <a href=http://www.researchmoz.com/b-cell-chronic-lymphocytic-leukemia-pipeline-review-h1-2013-report.html>B-Cell Chronic Lymphocytic Leukemia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/b-cell-chronic-lymphocytic-leukemia-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bronchopulmonary Dysplasia -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/bronchopulmonary-dysplasia-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/bronchopulmonary-dysplasia-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bronchopulmonary-dysplasia-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Bronchopulmonary Dysplasia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Bronchopulmonary Dysplasia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bronchopulmonary Dysplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchopulmonary Dysplasia. Bronchopulmonary Dysplasia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A  <br><br>Original Post <a href=http://www.researchmoz.com/bronchopulmonary-dysplasia-pipeline-review-h1-2013-report.html>Bronchopulmonary Dysplasia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Bronchopulmonary Dysplasia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Bronchopulmonary Dysplasia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bronchopulmonary Dysplasia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchopulmonary Dysplasia. Bronchopulmonary Dysplasia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A  <br><br>Original Post <a href=http://www.researchmoz.com/bronchopulmonary-dysplasia-pipeline-review-h1-2013-report.html>Bronchopulmonary Dysplasia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bronchopulmonary-dysplasia-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Friedreich Ataxia -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/friedreich-ataxia-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/friedreich-ataxia-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/friedreich-ataxia-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Friedreich Ataxia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Friedreich Ataxia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Friedreich Ataxia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Friedreich Ataxia. Friedreich Ataxia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/friedreich-ataxia-pipeline-review-h1-2013-report.html>Friedreich Ataxia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Friedreich Ataxia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Friedreich Ataxia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Friedreich Ataxia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Friedreich Ataxia. Friedreich Ataxia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/friedreich-ataxia-pipeline-review-h1-2013-report.html>Friedreich Ataxia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/friedreich-ataxia-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Secondary Hyperparathyroidism -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/secondary-hyperparathyroidism-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/secondary-hyperparathyroidism-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/secondary-hyperparathyroidism-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Secondary Hyperparathyroidism -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Secondary Hyperparathyroidism - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Secondary Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism. Secondary Hyperparathyroidism - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated di <br><br>Original Post <a href=http://www.researchmoz.com/secondary-hyperparathyroidism-pipeline-review-h1-2013-report.html>Secondary Hyperparathyroidism -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Secondary Hyperparathyroidism -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Secondary Hyperparathyroidism - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Secondary Hyperparathyroidism, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Secondary Hyperparathyroidism. Secondary Hyperparathyroidism - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated di <br><br>Original Post <a href=http://www.researchmoz.com/secondary-hyperparathyroidism-pipeline-review-h1-2013-report.html>Secondary Hyperparathyroidism -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/secondary-hyperparathyroidism-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Burkitt Lymphoma -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/burkitt-lymphoma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/burkitt-lymphoma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/burkitt-lymphoma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Burkitt Lymphoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Burkitt Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Burkitt Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma. Burkitt Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Bu <br><br>Original Post <a href=http://www.researchmoz.com/burkitt-lymphoma-pipeline-review-h1-2013-report.html>Burkitt Lymphoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Burkitt Lymphoma -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Burkitt Lymphoma - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Burkitt Lymphoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Burkitt Lymphoma. Burkitt Lymphoma - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Bu <br><br>Original Post <a href=http://www.researchmoz.com/burkitt-lymphoma-pipeline-review-h1-2013-report.html>Burkitt Lymphoma -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/burkitt-lymphoma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>H3N2 Infection -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/h3n2-infection-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/h3n2-infection-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/h3n2-infection-pipeline-review-h1-2013-report.html</guid><description><![CDATA[H3N2 Infection -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'H3N2 Infection - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for H3N2 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for H3N2 Infection. H3N2 Infection - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for H3N2 Infecti <br><br>Original Post <a href=http://www.researchmoz.com/h3n2-infection-pipeline-review-h1-2013-report.html>H3N2 Infection -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[H3N2 Infection -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'H3N2 Infection - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for H3N2 Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for H3N2 Infection. H3N2 Infection - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for H3N2 Infecti <br><br>Original Post <a href=http://www.researchmoz.com/h3n2-infection-pipeline-review-h1-2013-report.html>H3N2 Infection -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/h3n2-infection-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Memory Impairment -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/memory-impairment-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/memory-impairment-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/memory-impairment-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Memory Impairment -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Memory Impairment - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Memory Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Memory Impairment. Memory Impairment - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/memory-impairment-pipeline-review-h1-2013-report.html>Memory Impairment -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Memory Impairment -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Memory Impairment - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Memory Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Memory Impairment. Memory Impairment - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/memory-impairment-pipeline-review-h1-2013-report.html>Memory Impairment -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/memory-impairment-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Percutaneous Coronary Intervention -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/percutaneous-coronary-intervention-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/percutaneous-coronary-intervention-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/percutaneous-coronary-intervention-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Percutaneous Coronary Intervention -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Percutaneous Coronary Intervention - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Percutaneous Coronary Intervention, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Percutaneous Coronary Intervention. Percutaneous Coronary Intervention - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of  <br><br>Original Post <a href=http://www.researchmoz.com/percutaneous-coronary-intervention-pipeline-review-h1-2013-report.html>Percutaneous Coronary Intervention -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Percutaneous Coronary Intervention -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Percutaneous Coronary Intervention - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Percutaneous Coronary Intervention, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Percutaneous Coronary Intervention. Percutaneous Coronary Intervention - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of  <br><br>Original Post <a href=http://www.researchmoz.com/percutaneous-coronary-intervention-pipeline-review-h1-2013-report.html>Percutaneous Coronary Intervention -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/percutaneous-coronary-intervention-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Thymus Cancer -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/thymus-cancer-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/thymus-cancer-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/thymus-cancer-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Thymus Cancer -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Thymus Cancer - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Thymus Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thymus Cancer. Thymus Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Thymus Cancer.- A <br><br>Original Post <a href=http://www.researchmoz.com/thymus-cancer-pipeline-review-h1-2013-report.html>Thymus Cancer -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Thymus Cancer -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Thymus Cancer - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Thymus Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thymus Cancer. Thymus Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Thymus Cancer.- A <br><br>Original Post <a href=http://www.researchmoz.com/thymus-cancer-pipeline-review-h1-2013-report.html>Thymus Cancer -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/thymus-cancer-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Anesthetic Effect -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/anesthetic-effect-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/anesthetic-effect-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/anesthetic-effect-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Anesthetic Effect -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Anesthetic Effect - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Anesthetic Effect, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anesthetic Effect. Anesthetic Effect - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/anesthetic-effect-pipeline-review-h1-2013-report.html>Anesthetic Effect -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Anesthetic Effect -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Anesthetic Effect - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Anesthetic Effect, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anesthetic Effect. Anesthetic Effect - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/anesthetic-effect-pipeline-review-h1-2013-report.html>Anesthetic Effect -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/anesthetic-effect-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Athlete&#039;s Foot (Tinea Pedis) -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/athletes-foot-tinea-pedis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/athletes-foot-tinea-pedis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/athletes-foot-tinea-pedis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Athlete's Foot (Tinea Pedis) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Athlete's Foot (Tinea Pedis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Athlete's Foot (Tinea Pedis). Athlete's Foot (Tinea Pedis) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease <br><br>Original Post <a href=http://www.researchmoz.com/athletes-foot-tinea-pedis-pipeline-review-h1-2013-report.html>Athlete&#039;s Foot (Tinea Pedis) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Athlete's Foot (Tinea Pedis) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Athlete's Foot (Tinea Pedis) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Athlete's Foot (Tinea Pedis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Athlete's Foot (Tinea Pedis). Athlete's Foot (Tinea Pedis) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease <br><br>Original Post <a href=http://www.researchmoz.com/athletes-foot-tinea-pedis-pipeline-review-h1-2013-report.html>Athlete&#039;s Foot (Tinea Pedis) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/athletes-foot-tinea-pedis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cardiomyopathy -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/cardiomyopathy-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/cardiomyopathy-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cardiomyopathy-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Cardiomyopathy -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Cardiomyopathy - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cardiomyopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiomyopathy. Cardiomyopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Cardiomyopat <br><br>Original Post <a href=http://www.researchmoz.com/cardiomyopathy-pipeline-review-h1-2013-report.html>Cardiomyopathy -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Cardiomyopathy -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Cardiomyopathy - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cardiomyopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cardiomyopathy. Cardiomyopathy - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario for Cardiomyopat <br><br>Original Post <a href=http://www.researchmoz.com/cardiomyopathy-pipeline-review-h1-2013-report.html>Cardiomyopathy -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cardiomyopathy-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Chagas Disease (American Trypanosomiasis) -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/chagas-disease-american-trypanosomiasis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/chagas-disease-american-trypanosomiasis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/chagas-disease-american-trypanosomiasis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Chagas Disease (American Trypanosomiasis) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chagas Disease (American Trypanosomiasis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chagas Disease (American Trypanosomiasis). Chagas Disease (American Trypanosomiasis) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on <br><br>Original Post <a href=http://www.researchmoz.com/chagas-disease-american-trypanosomiasis-pipeline-review-h1-2013-report.html>Chagas Disease (American Trypanosomiasis) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Chagas Disease (American Trypanosomiasis) -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Chagas Disease (American Trypanosomiasis) - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chagas Disease (American Trypanosomiasis), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chagas Disease (American Trypanosomiasis). Chagas Disease (American Trypanosomiasis) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on <br><br>Original Post <a href=http://www.researchmoz.com/chagas-disease-american-trypanosomiasis-pipeline-review-h1-2013-report.html>Chagas Disease (American Trypanosomiasis) -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/chagas-disease-american-trypanosomiasis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Female Hypoactive Sexual Desire Disorder -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/female-hypoactive-sexual-desire-disorder-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/female-hypoactive-sexual-desire-disorder-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/female-hypoactive-sexual-desire-disorder-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Female Hypoactive Sexual Desire Disorder -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder. Female Hypoactive Sexual Desire Disorder - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the  <br><br>Original Post <a href=http://www.researchmoz.com/female-hypoactive-sexual-desire-disorder-pipeline-review-h1-2013-report.html>Female Hypoactive Sexual Desire Disorder -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Female Hypoactive Sexual Desire Disorder -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Female Hypoactive Sexual Desire Disorder - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Female Hypoactive Sexual Desire Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Hypoactive Sexual Desire Disorder. Female Hypoactive Sexual Desire Disorder - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the  <br><br>Original Post <a href=http://www.researchmoz.com/female-hypoactive-sexual-desire-disorder-pipeline-review-h1-2013-report.html>Female Hypoactive Sexual Desire Disorder -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/female-hypoactive-sexual-desire-disorder-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Hyperphosphatemia -  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/hyperphosphatemia-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/hyperphosphatemia-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 17 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/hyperphosphatemia-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Hyperphosphatemia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Hyperphosphatemia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hyperphosphatemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperphosphatemia. Hyperphosphatemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/hyperphosphatemia-pipeline-review-h1-2013-report.html>Hyperphosphatemia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Hyperphosphatemia -  Pipeline Review, H1 2013SummaryGlobal Markets Directs, 'Hyperphosphatemia - Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hyperphosphatemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperphosphatemia. Hyperphosphatemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- A snapshot of the global therapeutic scenario f <br><br>Original Post <a href=http://www.researchmoz.com/hyperphosphatemia-pipeline-review-h1-2013-report.html>Hyperphosphatemia -  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/hyperphosphatemia-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Breast Cancer  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/breast-cancer-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/breast-cancer-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/breast-cancer-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Breast Cancer Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Breast Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scenario  <br><br>Original Post <a href=http://www.researchmoz.com/breast-cancer-pipeline-review-h1-2013-report.html>Breast Cancer  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Breast Cancer Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Breast Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Breast Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Breast Cancer. Breast Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scenario  <br><br>Original Post <a href=http://www.researchmoz.com/breast-cancer-pipeline-review-h1-2013-report.html>Breast Cancer  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/breast-cancer-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Ovarian Cancer  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/ovarian-cancer-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/ovarian-cancer-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/ovarian-cancer-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Ovarian Cancer Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Ovarian Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. Ovarian Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scen <br><br>Original Post <a href=http://www.researchmoz.com/ovarian-cancer-pipeline-review-h1-2013-report.html>Ovarian Cancer  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Ovarian Cancer Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Ovarian Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ovarian Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ovarian Cancer. Ovarian Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scen <br><br>Original Post <a href=http://www.researchmoz.com/ovarian-cancer-pipeline-review-h1-2013-report.html>Ovarian Cancer  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/ovarian-cancer-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Lung Cancer  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/lung-cancer-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/lung-cancer-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/lung-cancer-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Lung Cancer Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Lung Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Cancer. Lung Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scenario for Lung Cance <br><br>Original Post <a href=http://www.researchmoz.com/lung-cancer-pipeline-review-h1-2013-report.html>Lung Cancer  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Lung Cancer Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Lung Cancer Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Lung Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Cancer. Lung Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scenario for Lung Cance <br><br>Original Post <a href=http://www.researchmoz.com/lung-cancer-pipeline-review-h1-2013-report.html>Lung Cancer  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/lung-cancer-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Inflammatory Bowel Disease  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/inflammatory-bowel-disease-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/inflammatory-bowel-disease-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/inflammatory-bowel-disease-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Inflammatory Bowel Disease Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Inflammatory Bowel Disease Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Inflammatory Bowel Disease Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. <br><br>Original Post <a href=http://www.researchmoz.com/inflammatory-bowel-disease-pipeline-review-h1-2013-report.html>Inflammatory Bowel Disease  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Inflammatory Bowel Disease Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Inflammatory Bowel Disease Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Inflammatory Bowel Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease. Inflammatory Bowel Disease Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. <br><br>Original Post <a href=http://www.researchmoz.com/inflammatory-bowel-disease-pipeline-review-h1-2013-report.html>Inflammatory Bowel Disease  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/inflammatory-bowel-disease-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Chronic Pain  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/chronic-pain-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/chronic-pain-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/chronic-pain-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Chronic Pain Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Chronic Pain Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chronic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Pain. Chronic Pain Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Chr <br><br>Original Post <a href=http://www.researchmoz.com/chronic-pain-pipeline-review-h1-2013-report.html>Chronic Pain  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Chronic Pain Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Chronic Pain Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chronic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chronic Pain. Chronic Pain Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Chr <br><br>Original Post <a href=http://www.researchmoz.com/chronic-pain-pipeline-review-h1-2013-report.html>Chronic Pain  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/chronic-pain-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Age Related Macular Degeneration  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/age-related-macular-degeneration-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/age-related-macular-degeneration-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/age-related-macular-degeneration-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Age Related Macular Degeneration Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Age Related Macular Degeneration Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Age Related Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration. Age Related Macular Degeneration Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of d <br><br>Original Post <a href=http://www.researchmoz.com/age-related-macular-degeneration-pipeline-review-h1-2013-report.html>Age Related Macular Degeneration  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Age Related Macular Degeneration Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Age Related Macular Degeneration Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Age Related Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Age Related Macular Degeneration. Age Related Macular Degeneration Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of d <br><br>Original Post <a href=http://www.researchmoz.com/age-related-macular-degeneration-pipeline-review-h1-2013-report.html>Age Related Macular Degeneration  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/age-related-macular-degeneration-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Depression  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/depression-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/depression-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/depression-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Depression Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Depression Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Depression Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Depression.
 <br><br>Original Post <a href=http://www.researchmoz.com/depression-pipeline-review-h1-2013-report.html>Depression  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Depression Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Depression Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Depression, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Depression. Depression Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Depression.
 <br><br>Original Post <a href=http://www.researchmoz.com/depression-pipeline-review-h1-2013-report.html>Depression  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/depression-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Congestive Heart Failure (Heart Failure)  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/congestive-heart-failure-heart-failure-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/congestive-heart-failure-heart-failure-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/congestive-heart-failure-heart-failure-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Congestive Heart Failure (Heart Failure) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Congestive Heart Failure (Heart Failure) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure). Congestive Heart Failure (Heart Failure) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered base <br><br>Original Post <a href=http://www.researchmoz.com/congestive-heart-failure-heart-failure-pipeline-review-h1-2013-report.html>Congestive Heart Failure (Heart Failure)  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Congestive Heart Failure (Heart Failure) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Congestive Heart Failure (Heart Failure) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Congestive Heart Failure (Heart Failure), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Congestive Heart Failure (Heart Failure). Congestive Heart Failure (Heart Failure) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered base <br><br>Original Post <a href=http://www.researchmoz.com/congestive-heart-failure-heart-failure-pipeline-review-h1-2013-report.html>Congestive Heart Failure (Heart Failure)  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/congestive-heart-failure-heart-failure-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Squamous Cell Carcinoma  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/squamous-cell-carcinoma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/squamous-cell-carcinoma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/squamous-cell-carcinoma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Squamous Cell Carcinoma Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Squamous Cell Carcinoma Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma. Squamous Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




 <br><br>Original Post <a href=http://www.researchmoz.com/squamous-cell-carcinoma-pipeline-review-h1-2013-report.html>Squamous Cell Carcinoma  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Squamous Cell Carcinoma Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Squamous Cell Carcinoma Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Squamous Cell Carcinoma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Squamous Cell Carcinoma. Squamous Cell Carcinoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




 <br><br>Original Post <a href=http://www.researchmoz.com/squamous-cell-carcinoma-pipeline-review-h1-2013-report.html>Squamous Cell Carcinoma  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/squamous-cell-carcinoma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cystic Fibrosis  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/cystic-fibrosis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/cystic-fibrosis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cystic-fibrosis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Cystic Fibrosis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Cystic Fibrosis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Cystic Fibrosis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic <br><br>Original Post <a href=http://www.researchmoz.com/cystic-fibrosis-pipeline-review-h1-2013-report.html>Cystic Fibrosis  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Cystic Fibrosis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Cystic Fibrosis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cystic Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cystic Fibrosis. Cystic Fibrosis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic <br><br>Original Post <a href=http://www.researchmoz.com/cystic-fibrosis-pipeline-review-h1-2013-report.html>Cystic Fibrosis  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cystic-fibrosis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Glioma  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/glioma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/glioma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/glioma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Glioma Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Glioma Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glioma. Glioma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scenario for Glioma.
A review of the Glioma <br><br>Original Post <a href=http://www.researchmoz.com/glioma-pipeline-review-h1-2013-report.html>Glioma  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Glioma Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Glioma Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Glioma. Glioma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scenario for Glioma.
A review of the Glioma <br><br>Original Post <a href=http://www.researchmoz.com/glioma-pipeline-review-h1-2013-report.html>Glioma  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/glioma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Wounds  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/wounds-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/wounds-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/wounds-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Wounds Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Wounds Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Wounds, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Wounds. Wounds Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scenario for Wounds.
A review of the Wounds <br><br>Original Post <a href=http://www.researchmoz.com/wounds-pipeline-review-h1-2013-report.html>Wounds  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Wounds Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Wounds Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Wounds, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Wounds. Wounds Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scenario for Wounds.
A review of the Wounds <br><br>Original Post <a href=http://www.researchmoz.com/wounds-pipeline-review-h1-2013-report.html>Wounds  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/wounds-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Kidney Cancer (Renal Cell Cancer)  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/kidney-cancer-renal-cell-cancer-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/kidney-cancer-renal-cell-cancer-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/kidney-cancer-renal-cell-cancer-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Kidney Cancer (Renal Cell Cancer) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Kidney Cancer (Renal Cell Cancer) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer (Renal Cell Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer (Renal Cell Cancer). Kidney Cancer (Renal Cell Cancer) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance <br><br>Original Post <a href=http://www.researchmoz.com/kidney-cancer-renal-cell-cancer-pipeline-review-h1-2013-report.html>Kidney Cancer (Renal Cell Cancer)  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Kidney Cancer (Renal Cell Cancer) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Kidney Cancer (Renal Cell Cancer) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Kidney Cancer (Renal Cell Cancer), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Kidney Cancer (Renal Cell Cancer). Kidney Cancer (Renal Cell Cancer) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance <br><br>Original Post <a href=http://www.researchmoz.com/kidney-cancer-renal-cell-cancer-pipeline-review-h1-2013-report.html>Kidney Cancer (Renal Cell Cancer)  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/kidney-cancer-renal-cell-cancer-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Traumatic Brain Injury  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/traumatic-brain-injury-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/traumatic-brain-injury-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/traumatic-brain-injury-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Traumatic Brain Injury Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Traumatic Brain Injury Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Traumatic Brain Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury. Traumatic Brain Injury Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A <br><br>Original Post <a href=http://www.researchmoz.com/traumatic-brain-injury-pipeline-review-h1-2013-report.html>Traumatic Brain Injury  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Traumatic Brain Injury Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Traumatic Brain Injury Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Traumatic Brain Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Traumatic Brain Injury. Traumatic Brain Injury Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A <br><br>Original Post <a href=http://www.researchmoz.com/traumatic-brain-injury-pipeline-review-h1-2013-report.html>Traumatic Brain Injury  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/traumatic-brain-injury-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Sarcomas  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/sarcomas-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/sarcomas-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/sarcomas-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Sarcomas Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Sarcomas Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sarcomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcomas. Sarcomas Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scenario for Sarcomas.
A review o <br><br>Original Post <a href=http://www.researchmoz.com/sarcomas-pipeline-review-h1-2013-report.html>Sarcomas  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Sarcomas Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Sarcomas Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sarcomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sarcomas. Sarcomas Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scenario for Sarcomas.
A review o <br><br>Original Post <a href=http://www.researchmoz.com/sarcomas-pipeline-review-h1-2013-report.html>Sarcomas  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/sarcomas-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Sepsis  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/sepsis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/sepsis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/sepsis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[
Sepsis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Sepsis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sepsis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sepsis. Sepsis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Sepsis.
A review of the Sepsis pro <br><br>Original Post <a href=http://www.researchmoz.com/sepsis-pipeline-review-h1-2013-report.html>Sepsis  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[
Sepsis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Sepsis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sepsis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sepsis. Sepsis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Sepsis.
A review of the Sepsis pro <br><br>Original Post <a href=http://www.researchmoz.com/sepsis-pipeline-review-h1-2013-report.html>Sepsis  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/sepsis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Sickle Cell Disease  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/sickle-cell-disease-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/sickle-cell-disease-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/sickle-cell-disease-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Sickle Cell Disease Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Sickle Cell Disease Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sickle Cell Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sickle Cell Disease. Sickle Cell Disease Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of th <br><br>Original Post <a href=http://www.researchmoz.com/sickle-cell-disease-pipeline-review-h1-2013-report.html>Sickle Cell Disease  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Sickle Cell Disease Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Sickle Cell Disease Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sickle Cell Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Sickle Cell Disease. Sickle Cell Disease Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of th <br><br>Original Post <a href=http://www.researchmoz.com/sickle-cell-disease-pipeline-review-h1-2013-report.html>Sickle Cell Disease  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/sickle-cell-disease-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Alcohol Addiction  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/alcohol-addiction-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/alcohol-addiction-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/alcohol-addiction-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Alcohol Addiction Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Alcohol Addiction Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Alcohol Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alcohol Addiction. Alcohol Addiction Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global the <br><br>Original Post <a href=http://www.researchmoz.com/alcohol-addiction-pipeline-review-h1-2013-report.html>Alcohol Addiction  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Alcohol Addiction Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Alcohol Addiction Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Alcohol Addiction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Alcohol Addiction. Alcohol Addiction Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global the <br><br>Original Post <a href=http://www.researchmoz.com/alcohol-addiction-pipeline-review-h1-2013-report.html>Alcohol Addiction  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/alcohol-addiction-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Pulmonary Arterial Hypertension  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/pulmonary-arterial-hypertension-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/pulmonary-arterial-hypertension-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/pulmonary-arterial-hypertension-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Pulmonary Arterial Hypertension Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Pulmonary Arterial Hypertension Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Arterial Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension. Pulmonary Arterial Hypertension Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data f <br><br>Original Post <a href=http://www.researchmoz.com/pulmonary-arterial-hypertension-pipeline-review-h1-2013-report.html>Pulmonary Arterial Hypertension  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Pulmonary Arterial Hypertension Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Pulmonary Arterial Hypertension Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Pulmonary Arterial Hypertension, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension. Pulmonary Arterial Hypertension Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data f <br><br>Original Post <a href=http://www.researchmoz.com/pulmonary-arterial-hypertension-pipeline-review-h1-2013-report.html>Pulmonary Arterial Hypertension  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/pulmonary-arterial-hypertension-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Diabetic Macular Edema  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/diabetic-macular-edema-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/diabetic-macular-edema-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/diabetic-macular-edema-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Diabetic Macular Edema Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Diabetic Macular Edema Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema. Diabetic Macular Edema Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A <br><br>Original Post <a href=http://www.researchmoz.com/diabetic-macular-edema-pipeline-review-h1-2013-report.html>Diabetic Macular Edema  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Diabetic Macular Edema Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Diabetic Macular Edema Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Diabetic Macular Edema, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Diabetic Macular Edema. Diabetic Macular Edema Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A <br><br>Original Post <a href=http://www.researchmoz.com/diabetic-macular-edema-pipeline-review-h1-2013-report.html>Diabetic Macular Edema  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/diabetic-macular-edema-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Systemic Sclerosis (Scleroderma)  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/systemic-sclerosis-scleroderma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/systemic-sclerosis-scleroderma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/systemic-sclerosis-scleroderma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Systemic Sclerosis (Scleroderma) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Systemic Sclerosis (Scleroderma) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma). Systemic Sclerosis (Scleroderma) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of d <br><br>Original Post <a href=http://www.researchmoz.com/systemic-sclerosis-scleroderma-pipeline-review-h1-2013-report.html>Systemic Sclerosis (Scleroderma)  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Systemic Sclerosis (Scleroderma) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Systemic Sclerosis (Scleroderma) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Systemic Sclerosis (Scleroderma), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Systemic Sclerosis (Scleroderma). Systemic Sclerosis (Scleroderma) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of d <br><br>Original Post <a href=http://www.researchmoz.com/systemic-sclerosis-scleroderma-pipeline-review-h1-2013-report.html>Systemic Sclerosis (Scleroderma)  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/systemic-sclerosis-scleroderma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Liver Fibrosis  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/liver-fibrosis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/liver-fibrosis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/liver-fibrosis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Liver Fibrosis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Liver Fibrosis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Liver Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Fibrosis. Liver Fibrosis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scen <br><br>Original Post <a href=http://www.researchmoz.com/liver-fibrosis-pipeline-review-h1-2013-report.html>Liver Fibrosis  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Liver Fibrosis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Liver Fibrosis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Liver Fibrosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Fibrosis. Liver Fibrosis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scen <br><br>Original Post <a href=http://www.researchmoz.com/liver-fibrosis-pipeline-review-h1-2013-report.html>Liver Fibrosis  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/liver-fibrosis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Escherichia Coli Infections  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/escherichia-coli-infections-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/escherichia-coli-infections-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/escherichia-coli-infections-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Escherichia Coli Infections Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Escherichia Coli Infections Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Escherichia Coli Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections. Escherichia Coli Infections Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated dis <br><br>Original Post <a href=http://www.researchmoz.com/escherichia-coli-infections-pipeline-review-h1-2013-report.html>Escherichia Coli Infections  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Escherichia Coli Infections Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Escherichia Coli Infections Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Escherichia Coli Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections. Escherichia Coli Infections Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated dis <br><br>Original Post <a href=http://www.researchmoz.com/escherichia-coli-infections-pipeline-review-h1-2013-report.html>Escherichia Coli Infections  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/escherichia-coli-infections-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Hyperlipidemia Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/hyperlipidemia-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/hyperlipidemia-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/hyperlipidemia-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Hyperlipidemia Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Hyperlipidemia Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hyperlipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperlipidemia. Hyperlipidemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scen <br><br>Original Post <a href=http://www.researchmoz.com/hyperlipidemia-pipeline-review-h1-2013-report.html>Hyperlipidemia Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Hyperlipidemia Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Hyperlipidemia Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Hyperlipidemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hyperlipidemia. Hyperlipidemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therapeutic scen <br><br>Original Post <a href=http://www.researchmoz.com/hyperlipidemia-pipeline-review-h1-2013-report.html>Hyperlipidemia Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/hyperlipidemia-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Mild Cognitive Impairment  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/mild-cognitive-impairment-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/mild-cognitive-impairment-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/mild-cognitive-impairment-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Mild Cognitive Impairment Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Mild Cognitive Impairment Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Mild Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment. Mild Cognitive Impairment Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

S <br><br>Original Post <a href=http://www.researchmoz.com/mild-cognitive-impairment-pipeline-review-h1-2013-report.html>Mild Cognitive Impairment  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Mild Cognitive Impairment Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Mild Cognitive Impairment Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Mild Cognitive Impairment, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Mild Cognitive Impairment. Mild Cognitive Impairment Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

S <br><br>Original Post <a href=http://www.researchmoz.com/mild-cognitive-impairment-pipeline-review-h1-2013-report.html>Mild Cognitive Impairment  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/mild-cognitive-impairment-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Acute Renal Failure (ARF) (Acute Kidney Injury)  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury). Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the re <br><br>Original Post <a href=http://www.researchmoz.com/acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h1-2013-report.html>Acute Renal Failure (ARF) (Acute Kidney Injury)  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Renal Failure (ARF) (Acute Kidney Injury). Acute Renal Failure (ARF) (Acute Kidney Injury) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the re <br><br>Original Post <a href=http://www.researchmoz.com/acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h1-2013-report.html>Acute Renal Failure (ARF) (Acute Kidney Injury)  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/acute-renal-failure-arf-acute-kidney-injury-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bile Duct Cancer (Cholangiocarcinoma)  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/bile-duct-cancer-cholangiocarcinoma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/bile-duct-cancer-cholangiocarcinoma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bile-duct-cancer-cholangiocarcinoma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) . Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the avai <br><br>Original Post <a href=http://www.researchmoz.com/bile-duct-cancer-cholangiocarcinoma-pipeline-review-h1-2013-report.html>Bile Duct Cancer (Cholangiocarcinoma)  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) . Bile Duct Cancer (Cholangiocarcinoma) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the avai <br><br>Original Post <a href=http://www.researchmoz.com/bile-duct-cancer-cholangiocarcinoma-pipeline-review-h1-2013-report.html>Bile Duct Cancer (Cholangiocarcinoma)  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bile-duct-cancer-cholangiocarcinoma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Ischemia Reperfusion Injury  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/ischemia-reperfusion-injury-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/ischemia-reperfusion-injury-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/ischemia-reperfusion-injury-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Ischemia Reperfusion Injury Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Ischemia Reperfusion Injury Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ischemia Reperfusion Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury. Ischemia Reperfusion Injury Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated dis <br><br>Original Post <a href=http://www.researchmoz.com/ischemia-reperfusion-injury-pipeline-review-h1-2013-report.html>Ischemia Reperfusion Injury  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Ischemia Reperfusion Injury Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Ischemia Reperfusion Injury Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Ischemia Reperfusion Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Ischemia Reperfusion Injury. Ischemia Reperfusion Injury Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated dis <br><br>Original Post <a href=http://www.researchmoz.com/ischemia-reperfusion-injury-pipeline-review-h1-2013-report.html>Ischemia Reperfusion Injury  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/ischemia-reperfusion-injury-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>T-Cell Lymphomas  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/t-cell-lymphomas-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/t-cell-lymphomas-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/t-cell-lymphomas-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

T-Cell Lymphomas Pipeline Review, H1 2013

Summary

Global Markets Directs, 'T-Cell Lymphomas Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas. T-Cell Lymphomas Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therap <br><br>Original Post <a href=http://www.researchmoz.com/t-cell-lymphomas-pipeline-review-h1-2013-report.html>T-Cell Lymphomas  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

T-Cell Lymphomas Pipeline Review, H1 2013

Summary

Global Markets Directs, 'T-Cell Lymphomas Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Lymphomas, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas. T-Cell Lymphomas Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A snapshot of the global therap <br><br>Original Post <a href=http://www.researchmoz.com/t-cell-lymphomas-pipeline-review-h1-2013-report.html>T-Cell Lymphomas  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/t-cell-lymphomas-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Lysosomal Storage Disorder  Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/lysosomal-storage-disorder-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/lysosomal-storage-disorder-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Wed, 10 Apr 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/lysosomal-storage-disorder-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Lysosomal Storage Disorder Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Lysosomal Storage Disorder Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Lysosomal Storage Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder. Lysosomal Storage Disorder Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. <br><br>Original Post <a href=http://www.researchmoz.com/lysosomal-storage-disorder-pipeline-review-h1-2013-report.html>Lysosomal Storage Disorder  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Lysosomal Storage Disorder Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Lysosomal Storage Disorder Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Lysosomal Storage Disorder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lysosomal Storage Disorder. Lysosomal Storage Disorder Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. <br><br>Original Post <a href=http://www.researchmoz.com/lysosomal-storage-disorder-pipeline-review-h1-2013-report.html>Lysosomal Storage Disorder  Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/lysosomal-storage-disorder-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Schizophrenia - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/schizophrenia-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/schizophrenia-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/schizophrenia-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Schizophrenia Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Schizophrenia Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Schizophrenia, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Schizophrenia. Schizophrenia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario  <br><br>Original Post <a href=http://www.researchmoz.com/schizophrenia-pipeline-review-h1-2013-report.html>Schizophrenia - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Schizophrenia Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Schizophrenia Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Schizophrenia, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Schizophrenia. Schizophrenia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario  <br><br>Original Post <a href=http://www.researchmoz.com/schizophrenia-pipeline-review-h1-2013-report.html>Schizophrenia - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/schizophrenia-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Influenza - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/influenza-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/influenza-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/influenza-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Influenza Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Influenza Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Influenza, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Influenza. Influenza Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Influenza.
A re <br><br>Original Post <a href=http://www.researchmoz.com/influenza-pipeline-review-h1-2013-report.html>Influenza - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Influenza Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Influenza Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Influenza, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Influenza. Influenza Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Influenza.
A re <br><br>Original Post <a href=http://www.researchmoz.com/influenza-pipeline-review-h1-2013-report.html>Influenza - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/influenza-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Non -Hodgkin Lymphoma - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/non-hodgkin-lymphoma-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/non-hodgkin-lymphoma-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/non-hodgkin-lymphoma-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Non -Hodgkin Lymphoma Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Non -Hodgkin Lymphoma Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non -Hodgkin Lymphoma, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non -Hodgkin Lymphoma. Non -Hodgkin Lymphoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A sn <br><br>Original Post <a href=http://www.researchmoz.com/non-hodgkin-lymphoma-pipeline-review-h1-2013-report.html>Non -Hodgkin Lymphoma - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Non -Hodgkin Lymphoma Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Non -Hodgkin Lymphoma Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Non -Hodgkin Lymphoma, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Non -Hodgkin Lymphoma. Non -Hodgkin Lymphoma Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope




A sn <br><br>Original Post <a href=http://www.researchmoz.com/non-hodgkin-lymphoma-pipeline-review-h1-2013-report.html>Non -Hodgkin Lymphoma - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/non-hodgkin-lymphoma-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Other Hematological Disorders - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/other-hematological-disorders-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/other-hematological-disorders-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/other-hematological-disorders-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Other Hematological Disorders Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Other Hematological Disorders Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Other Hematological Disorders, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Hematological Disorders. Other Hematological Disorders Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the i <br><br>Original Post <a href=http://www.researchmoz.com/other-hematological-disorders-pipeline-review-h1-2013-report.html>Other Hematological Disorders - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Other Hematological Disorders Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Other Hematological Disorders Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Other Hematological Disorders, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Other Hematological Disorders. Other Hematological Disorders Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the i <br><br>Original Post <a href=http://www.researchmoz.com/other-hematological-disorders-pipeline-review-h1-2013-report.html>Other Hematological Disorders - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/other-hematological-disorders-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Eosinophilic Esophagitis - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/eosinophilic-esophagitis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/eosinophilic-esophagitis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/eosinophilic-esophagitis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Eosinophilic Esophagitis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Eosinophilic Esophagitis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Eosinophilic Esophagitis, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis. Eosinophilic Esophagitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scop <br><br>Original Post <a href=http://www.researchmoz.com/eosinophilic-esophagitis-pipeline-review-h1-2013-report.html>Eosinophilic Esophagitis - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Eosinophilic Esophagitis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Eosinophilic Esophagitis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Eosinophilic Esophagitis, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Eosinophilic Esophagitis. Eosinophilic Esophagitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scop <br><br>Original Post <a href=http://www.researchmoz.com/eosinophilic-esophagitis-pipeline-review-h1-2013-report.html>Eosinophilic Esophagitis - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/eosinophilic-esophagitis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Rosacea - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/rosacea-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/rosacea-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/rosacea-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Rosacea Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Rosacea Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Rosacea, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rosacea. Rosacea Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Rosacea.
A review of the  <br><br>Original Post <a href=http://www.researchmoz.com/rosacea-pipeline-review-h1-2013-report.html>Rosacea - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Rosacea Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Rosacea Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Rosacea, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rosacea. Rosacea Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Rosacea.
A review of the  <br><br>Original Post <a href=http://www.researchmoz.com/rosacea-pipeline-review-h1-2013-report.html>Rosacea - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/rosacea-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Acute Respiratory Distress Syndrome - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/acute-respiratory-distress-syndrome-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/acute-respiratory-distress-syndrome-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/acute-respiratory-distress-syndrome-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Acute Respiratory Distress Syndrome Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Acute Respiratory Distress Syndrome Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome. Acute Respiratory Distress Syndrome Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability a <br><br>Original Post <a href=http://www.researchmoz.com/acute-respiratory-distress-syndrome-pipeline-review-h1-2013-report.html>Acute Respiratory Distress Syndrome - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Acute Respiratory Distress Syndrome Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Acute Respiratory Distress Syndrome Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome. Acute Respiratory Distress Syndrome Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability a <br><br>Original Post <a href=http://www.researchmoz.com/acute-respiratory-distress-syndrome-pipeline-review-h1-2013-report.html>Acute Respiratory Distress Syndrome - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/acute-respiratory-distress-syndrome-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Polycystic Kidney Disease - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/polycystic-kidney-disease-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/polycystic-kidney-disease-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/polycystic-kidney-disease-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Polycystic Kidney Disease Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Polycystic Kidney Disease Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Kidney Disease, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease. Polycystic Kidney Disease Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 <br><br>Original Post <a href=http://www.researchmoz.com/polycystic-kidney-disease-pipeline-review-h1-2013-report.html>Polycystic Kidney Disease - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Polycystic Kidney Disease Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Polycystic Kidney Disease Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Kidney Disease, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polycystic Kidney Disease. Polycystic Kidney Disease Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 <br><br>Original Post <a href=http://www.researchmoz.com/polycystic-kidney-disease-pipeline-review-h1-2013-report.html>Polycystic Kidney Disease - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/polycystic-kidney-disease-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Bronchiectasis - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/bronchiectasis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/bronchiectasis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/bronchiectasis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Bronchiectasis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Bronchiectasis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bronchiectasis, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchiectasis. Bronchiectasis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scen <br><br>Original Post <a href=http://www.researchmoz.com/bronchiectasis-pipeline-review-h1-2013-report.html>Bronchiectasis - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Bronchiectasis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Bronchiectasis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Bronchiectasis, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bronchiectasis. Bronchiectasis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scen <br><br>Original Post <a href=http://www.researchmoz.com/bronchiectasis-pipeline-review-h1-2013-report.html>Bronchiectasis - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/bronchiectasis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Fatigue - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/fatigue-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/fatigue-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/fatigue-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Fatigue Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Fatigue Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Fatigue, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fatigue. Fatigue Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Fatigue.
A review of the  <br><br>Original Post <a href=http://www.researchmoz.com/fatigue-pipeline-review-h1-2013-report.html>Fatigue - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Fatigue Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Fatigue Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Fatigue, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Fatigue. Fatigue Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Fatigue.
A review of the  <br><br>Original Post <a href=http://www.researchmoz.com/fatigue-pipeline-review-h1-2013-report.html>Fatigue - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/fatigue-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Leishmaniasis (Kala -Azar) - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/leishmaniasis-kala-azar-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/leishmaniasis-kala-azar-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/leishmaniasis-kala-azar-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Leishmaniasis (Kala -Azar) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Leishmaniasis (Kala -Azar) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Leishmaniasis (Kala -Azar), complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala -Azar). Leishmaniasis (Kala -Azar) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 <br><br>Original Post <a href=http://www.researchmoz.com/leishmaniasis-kala-azar-pipeline-review-h1-2013-report.html>Leishmaniasis (Kala -Azar) - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Leishmaniasis (Kala -Azar) Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Leishmaniasis (Kala -Azar) Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Leishmaniasis (Kala -Azar), complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Leishmaniasis (Kala -Azar). Leishmaniasis (Kala -Azar) Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 <br><br>Original Post <a href=http://www.researchmoz.com/leishmaniasis-kala-azar-pipeline-review-h1-2013-report.html>Leishmaniasis (Kala -Azar) - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/leishmaniasis-kala-azar-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Cachexia - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/cachexia-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/cachexia-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/cachexia-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Cachexia Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Cachexia Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cachexia, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cachexia. Cachexia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Cachexia.
A review o <br><br>Original Post <a href=http://www.researchmoz.com/cachexia-pipeline-review-h1-2013-report.html>Cachexia - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Cachexia Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Cachexia Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cachexia, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cachexia. Cachexia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Cachexia.
A review o <br><br>Original Post <a href=http://www.researchmoz.com/cachexia-pipeline-review-h1-2013-report.html>Cachexia - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/cachexia-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Allergic Conjunctivitis - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/allergic-conjunctivitis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/allergic-conjunctivitis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/allergic-conjunctivitis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Allergic Conjunctivitis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Allergic Conjunctivitis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Allergic Conjunctivitis, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis. Allergic Conjunctivitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



 <br><br>Original Post <a href=http://www.researchmoz.com/allergic-conjunctivitis-pipeline-review-h1-2013-report.html>Allergic Conjunctivitis - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Allergic Conjunctivitis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Allergic Conjunctivitis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Allergic Conjunctivitis, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Allergic Conjunctivitis. Allergic Conjunctivitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



 <br><br>Original Post <a href=http://www.researchmoz.com/allergic-conjunctivitis-pipeline-review-h1-2013-report.html>Allergic Conjunctivitis - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/allergic-conjunctivitis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Nosocomial Infections - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/nosocomial-infections-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/nosocomial-infections-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/nosocomial-infections-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Nosocomial Infections Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Nosocomial Infections Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Nosocomial Infections, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nosocomial Infections. Nosocomial Infections Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snap <br><br>Original Post <a href=http://www.researchmoz.com/nosocomial-infections-pipeline-review-h1-2013-report.html>Nosocomial Infections - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Nosocomial Infections Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Nosocomial Infections Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Nosocomial Infections, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nosocomial Infections. Nosocomial Infections Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snap <br><br>Original Post <a href=http://www.researchmoz.com/nosocomial-infections-pipeline-review-h1-2013-report.html>Nosocomial Infections - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/nosocomial-infections-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Acromegaly - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/acromegaly-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/acromegaly-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/acromegaly-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Acromegaly Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Acromegaly Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Acromegaly, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acromegaly. Acromegaly Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Acromegaly. <br><br>Original Post <a href=http://www.researchmoz.com/acromegaly-pipeline-review-h1-2013-report.html>Acromegaly - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Acromegaly Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Acromegaly Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Acromegaly, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acromegaly. Acromegaly Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for Acromegaly. <br><br>Original Post <a href=http://www.researchmoz.com/acromegaly-pipeline-review-h1-2013-report.html>Acromegaly - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/acromegaly-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Female Sexual Dysfunction - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/female-sexual-dysfunction-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/female-sexual-dysfunction-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/female-sexual-dysfunction-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Female Sexual Dysfunction Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Female Sexual Dysfunction Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Female Sexual Dysfunction, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction. Female Sexual Dysfunction Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Sco <br><br>Original Post <a href=http://www.researchmoz.com/female-sexual-dysfunction-pipeline-review-h1-2013-report.html>Female Sexual Dysfunction - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Female Sexual Dysfunction Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Female Sexual Dysfunction Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Female Sexual Dysfunction, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Female Sexual Dysfunction. Female Sexual Dysfunction Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Sco <br><br>Original Post <a href=http://www.researchmoz.com/female-sexual-dysfunction-pipeline-review-h1-2013-report.html>Female Sexual Dysfunction - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/female-sexual-dysfunction-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Lung Disease - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/lung-disease-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/lung-disease-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/lung-disease-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Lung Disease Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Lung Disease Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Lung Disease, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Disease. Lung Disease Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for L <br><br>Original Post <a href=http://www.researchmoz.com/lung-disease-pipeline-review-h1-2013-report.html>Lung Disease - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Lung Disease Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Lung Disease Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Lung Disease, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Disease. Lung Disease Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for L <br><br>Original Post <a href=http://www.researchmoz.com/lung-disease-pipeline-review-h1-2013-report.html>Lung Disease - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/lung-disease-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Moderate Psoriasis - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/moderate-psoriasis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/moderate-psoriasis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/moderate-psoriasis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Moderate Psoriasis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Moderate Psoriasis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Moderate Psoriasis, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Psoriasis. Moderate Psoriasis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the glo <br><br>Original Post <a href=http://www.researchmoz.com/moderate-psoriasis-pipeline-review-h1-2013-report.html>Moderate Psoriasis - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Moderate Psoriasis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Moderate Psoriasis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Moderate Psoriasis, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Moderate Psoriasis. Moderate Psoriasis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the glo <br><br>Original Post <a href=http://www.researchmoz.com/moderate-psoriasis-pipeline-review-h1-2013-report.html>Moderate Psoriasis - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/moderate-psoriasis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Perennial Allergic Rhinitis - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/perennial-allergic-rhinitis-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/perennial-allergic-rhinitis-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/perennial-allergic-rhinitis-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Perennial Allergic Rhinitis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Perennial Allergic Rhinitis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Perennial Allergic Rhinitis, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis. Perennial Allergic Rhinitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated d <br><br>Original Post <a href=http://www.researchmoz.com/perennial-allergic-rhinitis-pipeline-review-h1-2013-report.html>Perennial Allergic Rhinitis - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Perennial Allergic Rhinitis Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Perennial Allergic Rhinitis Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Perennial Allergic Rhinitis, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Perennial Allergic Rhinitis. Perennial Allergic Rhinitis Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated d <br><br>Original Post <a href=http://www.researchmoz.com/perennial-allergic-rhinitis-pipeline-review-h1-2013-report.html>Perennial Allergic Rhinitis - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/perennial-allergic-rhinitis-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Typhoid Fever - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/typhoid-fever-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/typhoid-fever-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/typhoid-fever-pipeline-review-h1-2013-report.html</guid><description><![CDATA[Typhoid Fever Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Typhoid Fever Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Typhoid Fever, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Typhoid Fever. Typhoid Fever Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for  <br><br>Original Post <a href=http://www.researchmoz.com/typhoid-fever-pipeline-review-h1-2013-report.html>Typhoid Fever - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[Typhoid Fever Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Typhoid Fever Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Typhoid Fever, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Typhoid Fever. Typhoid Fever Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope



A snapshot of the global therapeutic scenario for  <br><br>Original Post <a href=http://www.researchmoz.com/typhoid-fever-pipeline-review-h1-2013-report.html>Typhoid Fever - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/typhoid-fever-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item><item><title>Klebsiella Pneumoniae Infections - Pipeline Review, H1 2013</title><link>http://www.researchmoz.com/klebsiella-pneumoniae-infections-pipeline-review-h1-2013-report.html</link><comments>http://www.researchmoz.com/klebsiella-pneumoniae-infections-pipeline-review-h1-2013-report.html#comments</comments><pubDate>Thu, 28 Mar 2013 00:00:00 -0500</pubDate><dc:creator>admin</dc:creator><guid isPermaLink='false'>http://www.researchmoz.com/klebsiella-pneumoniae-infections-pipeline-review-h1-2013-report.html</guid><description><![CDATA[

Klebsiella Pneumoniae Infections Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Klebsiella Pneumoniae Infections Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections. Klebsiella Pneumoniae Infections Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of <br><br>Original Post <a href=http://www.researchmoz.com/klebsiella-pneumoniae-infections-pipeline-review-h1-2013-report.html>Klebsiella Pneumoniae Infections - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></description><content:encoded><![CDATA[

Klebsiella Pneumoniae Infections Pipeline Review, H1 2013

Summary

Global Markets Directs, 'Klebsiella Pneumoniae Infections Pipeline Review, H1 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Klebsiella Pneumoniae Infections, complete with latest updates, and special features on late -stage and discontinued projects. It also reviews key players involved in the therapeutic development for Klebsiella Pneumoniae Infections. Klebsiella Pneumoniae Infections Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry -specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of <br><br>Original Post <a href=http://www.researchmoz.com/klebsiella-pneumoniae-infections-pipeline-review-h1-2013-report.html>Klebsiella Pneumoniae Infections - Pipeline Review, H1 2013</a> <br> source  <a href="http://www.researchmoz.com">Researchmoz</a>]]></content:encoded><wfw:commentRss>http://www.researchmoz.com/klebsiella-pneumoniae-infections-pipeline-review-h1-2013-report.html/feed</wfw:commentRss><slash:comments>0</slash:comments>	</item></channel></rss>